We recently published a list of the 11 Best Pharma Stocks to Buy According to Hedge Funds. In this article, we are going to ...

Amgen released financial results for the 4th quarter of 2024. Check out why I continue to cover AMGN stock with a 'Buy' rating.

With what analysts are calling "strong" data, Amgen plans to file a regulatory submission for Uplizna, currently approved for ...

Amgen and CytomX Therapeutics have kicked a phase 1 T-cell engager to the curb, axing the asset after assessing the clinical ...

Amgen is advancing a broad and deep pipeline that builds on its existing portfolio of medicines to treat cancer, heart disease, osteoporosis, inflammatory diseases and rare diseases.

We recently published a list of Dobermans of the Dow: 10 Stocks to Consider. In this article, we are going to take a look at where Amgen Inc. (NASDAQ:AMGN) stands against other Dobermans of the ...

In September 2024, a readout from a separate trial of rocatinlimab elicited mixed reactions from analysts, who found the ...

Michael Castagna became CEO of MannKind and joined its board of directors in 2017, bringing 25+ years’ experience in ...

Healthcare Analysts discuss Amgen’s ( AMGN) Late-Stage Pipeline In The Rare Autoimmune Disease Arena on an Analyst/Industry conference call to be held on March 7. Published first on TheFly – the ...